Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-9131 + bictegravir + tenofovir alafenamide
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination regimen of three antiretroviral agents for HIV-1 infection: **GS-9131 (rovafovir)**, an investigational nucleotide reverse transcriptase inhibitor (NRTI) prodrug with potent activity even against NRTI-resistant HIV-1; **bictegravir**, a marketed integrase strand transfer inhibitor (INSTI); and **tenofovir alafenamide**, a prodrug of tenofovir and established NRTI. GS-9131 (also known as rovafovir) is a phosphonoamidate prodrug of GS-9148 designed for improved delivery and intracellular conversion, offering a unique resistance profile and favorable toxicity; bictegravir blocks the integration of viral DNA into host DNA; tenofovir alafenamide is a more targeted tenofovir prodrug for lower toxicity and potent viral suppression. This combination aims to provide a potent, broad-spectrum antiretroviral effect through simultaneous inhibition of reverse transcriptase (by two drugs with distinct resistance profiles) and integrase[2][3][4][1].
- Other names
- rovafovir + bictegravir + tenofovir alafenamide
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseIntegrase allosteric pocket (HIV)
Beyond the preview
Go deeper on GS-9131 + bictegravir + tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-9131 + bictegravir + tenofovir alafenamide.